Bicara Therapeutics (NASDAQ:BCAX) Stock Price Down 4.5% – Should You Sell?

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) were down 4.5% on Tuesday . The stock traded as low as $12.68 and last traded at $12.88. Approximately 52,442 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 342,036 shares. The stock had previously closed at $13.48.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on BCAX. Rodman & Renshaw started coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating and a $48.00 price objective on the stock. RODMAN&RENSHAW upgraded Bicara Therapeutics to a “strong-buy” rating in a report on Tuesday, November 5th. HC Wainwright lifted their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. Finally, Wedbush restated an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research report on Wednesday, February 12th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $41.20.

Bicara Therapeutics Price Performance

The business’s 50 day moving average price is $14.83.

Institutional Trading of Bicara Therapeutics

A number of hedge funds have recently modified their holdings of the company. First Turn Management LLC bought a new stake in Bicara Therapeutics in the third quarter valued at approximately $14,324,000. Geode Capital Management LLC acquired a new position in shares of Bicara Therapeutics in the 3rd quarter valued at $1,239,000. Vestal Point Capital LP bought a new stake in shares of Bicara Therapeutics in the 3rd quarter valued at $10,825,000. FMR LLC acquired a new stake in Bicara Therapeutics during the 3rd quarter worth $57,913,000. Finally, Braidwell LP acquired a new stake in Bicara Therapeutics during the 3rd quarter worth $42,219,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.